Evergreening by whom? A review of secondary patents for omeprazole

Author： Lloyd Mike  

Publisher： Future Science

ISSN： 2046-8954

Source： Pharmaceutical Patent Analyst, Vol.2, Iss.6, 2013-11, pp. : 737-743

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Omeprazole: Hypocalcaemic seizures secondary to hypomagnesaemia: 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1216, 2008-01 ,pp. : 26-27

Adis International

Access to resources Recommend Favorite

Review of immediate-release omeprazole for the treatment of gastric acid-related disorders

By Castell Donald  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 14, 2005-11 ,pp. : 2501-2510

Informa Healthcare

Access to resources Recommend Favorite

5-Lipoxygenase inhibitors: a review of recent developments and patents

By Pergola Carlo   Werz Oliver  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 3, 2010-03 ,pp. : 355-375

Informa Healthcare

Access to resources Recommend Favorite

Monoclonal antibodies for immunological disorders: a review of recent patents

By Andreakos Evangelos  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 9, 2005-09 ,pp. : 1105-1114

Informa Healthcare

Access to resources Recommend Favorite

The search for new DHFR inhibitors: a review of patents, January 2001 – February 2005

By da Cunha Elaine Fontes F   Ramalho Teodorico C   Maia Elaine R   de Alencastro Ricardo Bicca  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 8, 2005-08 ,pp. : 967-986

Informa Healthcare

Access to resources Recommend Favorite